Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05002842
Other study ID # 1703S09842
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 1, 2018
Est. completion date December 1, 2018

Study information

Verified date May 2023
Source University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CaringBridge (CB) is an online health community for people undergoing challenging health journeys. This platform provides an opportunity for individuals and their caregivers to rally support for a loved-one during a health journey. CaringBridge offers the opportunity for expressive writing through journal entries, wellbeing resources, participant health journey stories, and practical scheduling and communication tools to support community, healing, and wellbeing. Loving Kindness Meditation (LKM) is a systemized mind-body approach developed to increase loving acceptance and has been shown to increase resilience in the face of adversity. The aim of this study is to better understand how mind-body practices, like LKM, impact adult CB users


Recruitment information / eligibility

Status Completed
Enrollment 979
Est. completion date December 1, 2018
Est. primary completion date December 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - English literacy - CaringBridge user with an active email address - Visitor/Caregiver/Patient on a Cancer Journey (for Phase 2 only) Exclusion Criteria: - N/A

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
LovingKindess Meditation
Participants will have access to a recording of a script to guide them through meditation

Locations

Country Name City State
United States University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Perceived Stress: The Perceived Stress Scale The Perceived Stress Scale is a 10-item scale for measuring one's perception of stress. All 10 items are assessed by asking how often a respondent felt a certain way on a 5-point Likert measure (0 = Never; 4 = Very Often), with a minimum score of 0 and a maximum score of 40. Higher total scores indicate greater perceived stress.
This will be assessed at baseline and week three, in addition to week six for the deferred arm.
3 weeks
Secondary Change in Self-Compassion: The Self-Compassion Scale The Self-Compassion Scale (SCS) is a 12-item, shortened version of the original longer 26-item self-compassion scale (range 12-60). The 12-item SCS contains the same higher-order factor structure as the 26-item scale with a general Higher-Order Self-Compassion factor and six second-order factors of Self-Kindness, Self-Judgement, Common Humanity, Isolation, Mindfulness, and Over-Identification. All 12 items are assessed by asking how often a respondent felt a certain way on a 5-point Likert measure (1 =Almost never; 5 =Almost always). Higher SCS scores are associated with psychological well-being and suggest self-compassion might be an important protective factor, fostering emotional resilience.
This will be assessed at baseline and week three, in addition to week six for the deferred arm.
3 weeks
Secondary Change in Compassionate Love: The Compassionate Love for Humanity Scale The Compassionate Love Scale (CLS) is a 21-item measure of the stranger-humanity version of the original CLS designed to measure compassionate love for humanity (range 38-147). Higher CLS scores indicate greater compassionate love for humanity.
This will be assessed at baseline and week three, in addition to week six for the deferred arm.
3 weeks
Secondary Change in Social Support: The Social Connectedness Scale Social connectedness is assessed with 8 items on a 6-point Likert scale (1 = strongly agree through 6 = strongly disagree), with a total range of 8-48. Social connectedness is reverse coded such that high scores indicate higher social connection.
This will be assessed at baseline and week three, in addition to week six for the deferred arm.
3 weeks
Secondary Change in Social Support: The Social Assurance Scale Social assurance is assessed with 8 items on a 6-point Likert scale (1 = strongly agree through 6 = strongly disagree), with a total range of 8-48. Social Assurance is reverse coded such that high scores indicate higher social assurance. This will be assessed at baseline and week three, in addition to week six for the deferred arm. 3 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases